Tools

Explore

Videos Channels Figures

Atmrix

Tools

Explore

Videos Channels Figures

Atmrix

EI

Elizabeth Iorns

09/14/17

@ Y Combinator

During the three-month Y Combinator program, biotech companies focus on refining their go-to-market strategy and understanding market requirements, which helps them secure necessary funding and capital.

Video

Elizabeth Iorns on Biotech Companies in YC

@ Y Combinator

Elizabeth Iorns on Biotech Companies in YC

09/14/17

Related Takeaways

Elizabeth Iorns

09/14/17

@ Y Combinator

Biotech companies often use their time in Y Combinator to conduct critical path experiments and work with external companies for proof of concept studies, which can advance their regulatory filing status.

Y Combinator Cast

01/13/21

@ Y Combinator

During the three-month Y Combinator program, the entire team focuses solely on growing the company and its numbers, which is extremely beneficial.

Elizabeth Iorns

09/14/17

@ Y Combinator

Biotech companies benefit from Y Combinator through access to capital, fundraising expertise, and interaction with diverse sectors, which can lead to unexpected advantages.

Elizabeth Iorns

09/14/17

@ Y Combinator

Programs like Y Combinator offer frameworks and confidence for entrepreneurs, clarifying the risks and opportunities in starting a biotech company.

Elizabeth Iorns

09/14/17

@ Y Combinator

Y Combinator helps biotech companies develop strategies for licensing intellectual property, which is essential for their growth.

Alexis Ohanian

06/20/14

@ Y Combinator

These Y Combinator companies spent three months in Silicon Valley, leveraging the network before returning to New York to grow their businesses.

Elizabeth Irans

02/24/15

@ Y Combinator

Biotech and medical device companies have shown success in the YC program, benefiting from focused milestones during the three-month period.

Elizabeth Iorns

09/14/17

@ Y Combinator

There's a significant gap in funding for early-stage biotech discoveries, leading many companies to apply to Y Combinator when they have initial data suggesting a promising approach to curing diseases.

Elizabeth Iorns

09/14/17

@ Y Combinator

Many biotech companies have raised significantly more capital through Y Combinator than they would have in traditional biotech venture settings, with over $200 million raised for these companies.